论文部分内容阅读
目的探讨白介素-8(IL-8)能否作为T2DM视网膜病抗血管内皮生长因子(VEGF)治疗的联合治疗靶点。方法 T2DM患者112例,按有无并发症分为单纯T2DM组和糖尿病视网膜病变(DR)组。同时收集健康体检者36名为健康对照组(NC组)。放射免疫法(RIA)测定受试者血清VEGF和IL-8含量。结果 T2DM组与DR组VEGF含量较NC组分别升高1.73倍[(5.26±3.54)vs(9.10±4.85)ng/ml,P<0.05)和4.53倍[(5.26±3.54)vs(23.86±16.16)ng/ml,P<0.05)],DR组较T2DM组升高2.62倍[(9.10±4.85)vs(23.86±16.16)ng/ml,P<0.05)];T2DM组与DR组IL-8含量与NC组比较分别升高7.42倍[(25.69±2.47)vs(190.50±27.17)ng/ml,P<0.05)]和69.72倍[(25.69±2.47)vs(1791.00±297.30)ng/ml,P<0.05)],DR组较T2DM组升高9.4倍[(190.50±27.17)vs(1791.00±297.30)ng/ml,P<0.05)]。VEGF曲线下面积(AUC)为0.89,95%CI为0.84~0.94(P<0.001);IL-8的AUC为0.82,95%CI为0.75~0.89(P<0.001)。在NC组中,血清IL-8与VEGF含量无相关性(r=0.1232,P>0.05),但在T2DM组和DR组中,IL-8与VEGF呈正相关(r=0.6128、0.8671,P<0.05)。结论 IL-8可作为DR抗VEGF治疗的联合治疗靶点和危险评估因素。
Objective To investigate whether interleukin-8 (IL-8) can be used as a combined therapeutic target for the treatment of T2DM retinal vascular endothelial growth factor (VEGF). Methods One hundred and twelve patients with T2DM were divided into simple T2DM group and diabetic retinopathy group with and without complications. Meanwhile, 36 healthy subjects were collected as healthy control group (NC group). Radioimmunoassay (RIA) was used to determine the serum levels of VEGF and IL-8 in the subjects. Results The VEGF levels in T2DM group and DR group were 1.73 times higher than those in NC group [(5.26 ± 3.54) vs (9.10 ± 4.85) ng / ml, P <0.05) and 4.53 times (5.26 ± 3.54 vs 23.86 ± 16.16 ) (P <0.05). Compared with T2DM group, the level of IL-8 in DR group was significantly higher than that in T2DM group (9.10 ± 4.85 vs 23.86 ± 16.16 ng / ml, P < (25.69 ± 2.47) vs (190.50 ± 27.17) ng / ml, P <0.05) and 69.72 times [(25.69 ± 2.47) vs (1791.00 ± 297.30) ng / ml, P <0.05). Compared with T2DM group, the level of DR in group DR increased 9.4 times (190.50 ± 27.17 vs 1791.00 ± 297.30 ng / ml, P 0.05). The area under the curve of VEGF (AUC) was 0.89, the 95% CI was 0.84 to 0.94 (P <0.001), the AUC of IL-8 was 0.82, and the 95% CI was 0.75 to 0.89 (P <0.001). There was no correlation between IL-8 and VEGF in NC group (r = 0.1232, P> 0.05), but there was a positive correlation between IL-8 and VEGF in T2DM group and DR group (r = 0.6128,0.8671, P < 0.05). Conclusion IL-8 can be used as a combined therapy target and risk assessment factor for DR anti-VEGF therapy.